Skip to content

What is the pink pleasure pill? Understanding Addyi (Flibanserin) and HSDD

3 min read

According to the American Sexual Health Association, approximately one in ten women have hypoactive sexual desire disorder (HSDD), a condition that can cause significant distress. For premenopausal women dealing with this issue, the "pink pleasure pill"—more accurately known by its brand name, Addyi (flibanserin)—emerged as a treatment option in 2015.

Quick Summary

The term 'pink pleasure pill' refers to Addyi (flibanserin), a daily oral medication approved by the FDA for hypoactive sexual desire disorder (HSDD) in premenopausal women. It alters brain chemistry to increase sexual desire, unlike male erectile dysfunction drugs.

Key Points

  • Name and Purpose: The 'pink pleasure pill' is Addyi (flibanserin), a daily oral medication approved for premenopausal women with Hypoactive Sexual Desire Disorder (HSDD).

  • Mechanism of Action: Addyi works on brain chemicals like serotonin and dopamine to increase sexual desire, unlike male libido drugs which increase blood flow.

  • Serious Side Effect: Combining Addyi with alcohol carries a black box warning due to a high risk of severe low blood pressure and fainting.

  • Alternative Treatment: Vyleesi (bremelanotide) is another FDA-approved HSDD treatment, administered as an on-demand injection before sex, with common side effects including nausea and flushing.

  • Holistic Approach: HSDD treatment can also involve psychotherapy (including sex therapy and CBT), lifestyle modifications, and addressing underlying physical or relational issues.

  • No 'Female Viagra': Calling Addyi or Vyleesi 'female Viagra' is misleading and incorrect, as their mechanisms are fundamentally different from erectile dysfunction medications.

In This Article

What is the pink pleasure pill (Addyi)?

The "pink pleasure pill" is the common nickname for Addyi (flibanserin), an oral medication approved by the U.S. Food and Drug Administration (FDA) in 2015. It is specifically for premenopausal women diagnosed with acquired, generalized hypoactive sexual desire disorder (HSDD). HSDD is characterized by a persistent lack of sexual fantasies and desire causing distress, not attributable to other conditions, relationship issues, or other medications. Originally intended as an antidepressant, flibanserin was found to impact libido during trials. Addyi is taken once daily at bedtime.

How Addyi works: A different mechanism from Viagra

Addyi is not "female Viagra"; they function differently. While Viagra increases blood flow to treat erectile dysfunction, Addyi acts on the brain. It modulates neurotransmitters like serotonin, dopamine, and norepinephrine to help restore the balance needed for sexual desire. This means it requires daily use, not just before sexual activity, to potentially see modest effects.

Side effects and safety precautions

A major concern with Addyi is severe low blood pressure and fainting, especially when combined with alcohol, leading to an FDA black box warning and strict alcohol avoidance guidelines. Common side effects include dizziness, sleepiness, nausea, fatigue, and dry mouth. Insomnia, constipation, and abdominal pain are less common. Due to risks, only certified healthcare providers can prescribe Addyi. It's not for those with liver problems and shouldn't be taken with certain medications, including some antibiotics and antifungals.

Another option: The as-needed injection Vyleesi

In 2019, the FDA approved Vyleesi (bremelanotide) as a second HSDD treatment for premenopausal women. Vyleesi is a self-administered injection taken into the abdomen or thigh at least 45 minutes before anticipated sex. It works by activating melanocortin receptors in the brain. Like Addyi, Vyleesi's effects can be modest. Side effects include nausea (potentially severe), flushing, and injection site reactions. It can also temporarily raise blood pressure and lower heart rate. There are no alcohol restrictions with Vyleesi.

Comparing Addyi and Vyleesi

Feature Addyi (Flibanserin) Vyleesi (Bremelanotide)
Mechanism of Action Modulates brain serotonin and dopamine Activates melanocortin receptors in the brain
Formulation Oral tablet Subcutaneous injection
Timing of Use Daily, at bedtime As-needed, at least 45 mins before sex
Key Side Effects Dizziness, sleepiness, nausea, fainting (esp. with alcohol) Nausea (can be severe), flushing, headache, injection site reactions
Alcohol Restriction Yes, significant risk of severe hypotension No, but can cause a brief rise in blood pressure

Beyond medication: Other treatment approaches for HSDD

HSDD is complex, often stemming from psychological, relational, or physical factors. Treatment frequently involves a combination of approaches beyond medication:

  • Psychotherapy: Sex therapy, couples therapy, or CBT can help address underlying issues.
  • Lifestyle changes: Improving sleep, managing stress, exercise, and open communication with a partner can enhance sexual health.
  • Hormonal therapy: Localized vaginal estrogen may help postmenopausal women with dryness and pain, indirectly improving desire. Testosterone use for HSDD is not FDA-approved and requires caution.
  • Managing other medications: Certain drugs, like SSRI antidepressants, can reduce libido. Adjusting dosage or switching medications may be necessary.

Conclusion

The "pink pleasure pill," or Addyi (flibanserin), is a daily oral treatment for premenopausal women with HSDD. It's important to understand it's not a quick fix or an aphrodisiac like male ED drugs. Both Addyi and Vyleesi, a newer as-needed injection, work differently than blood flow enhancers. Women should discuss the root cause of low libido with a healthcare provider to explore all safe and effective options, including medication, therapy, and lifestyle changes, recognizing that a single pill isn't a magical solution.

Frequently Asked Questions

Addyi (flibanserin) is a daily oral pill that works on brain neurotransmitters to increase desire over time. Vyleesi (bremelanotide) is an on-demand injection taken before sexual activity, which targets different receptors in the brain.

Combining Addyi with alcohol significantly increases the risk of severe low blood pressure (hypotension) and fainting (syncope). The FDA mandates a strict warning to avoid alcohol consumption when using this medication.

No, Addyi (flibanserin) is only approved for use in premenopausal women. Neither Addyi nor Vyleesi is approved for use in postmenopausal women, though other options may be available.

The effects of Addyi are often described as modest and not immediate. Clinical trial data suggests it can take at least 8 weeks to determine if the medication is providing any benefit.

Yes, many women can benefit from non-medication approaches. These include sex therapy, couples counseling, lifestyle changes like exercise and improved sleep, and treating underlying medical conditions.

Clinical trials for Addyi showed that it resulted in a small increase in satisfying sexual events per month for some women. However, it is not guaranteed to increase desire or satisfaction for every individual.

Numerous factors can affect libido, including chronic illnesses like diabetes and thyroid problems, medications (e.g., antidepressants, hormonal contraceptives), relationship issues, and psychological factors like anxiety and depression.

References

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10

Medical Disclaimer

This content is for informational purposes only and should not replace professional medical advice.